Published in Blood on August 18, 2005
Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH). Thromb Haemost (2012) 1.45
Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery. Blood (2015) 1.43
Determinants of PF4/heparin immunogenicity. Blood (2007) 1.25
New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol (2011) 1.11
Diagnosis and management of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am (2013) 1.10
Heparin-induced thrombocytopenia. Annu Rev Med (2010) 0.95
The incidence, causes, and prognostic significance of new-onset thrombocytopenia in intensive care units: a prospective cohort study in a Korean hospital. J Korean Med Sci (2012) 0.90
Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia. Ther Adv Hematol (2012) 0.87
Heparin-induced thrombocytopenia in the ICU: an overview. Crit Care (2011) 0.85
Fondaparinux-associated heparin-induced thrombocytopenia. Proc (Bayl Univ Med Cent) (2012) 0.85
Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results. J Thromb Thrombolysis (2008) 0.82
Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach. Ther Clin Risk Manag (2011) 0.79
Platelet factor 4/heparin antibodies in blood bank donors. Am J Clin Pathol (2010) 0.79
Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia. Thromb J (2013) 0.79
IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics. BMC Musculoskelet Disord (2011) 0.78
Effects of a Foot Pump on the Incidence of Deep Vein Thrombosis After Total Knee Arthroplasty in Patients Given Edoxaban: A Randomized Controlled Study. Medicine (Baltimore) (2016) 0.78
Atomic description of the immune complex involved in heparin-induced thrombocytopenia. Nat Commun (2015) 0.78
Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacement. BMC Musculoskelet Disord (2009) 0.78
Prevention and treatment of venous thromboembolism in the elderly patient. Clin Interv Aging (2007) 0.77
The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes. Ther Clin Risk Manag (2008) 0.77
Inhibitors of propagation of coagulation: factors V and X. Br J Clin Pharmacol (2011) 0.76
The Pharmacotherapy of Heparin-Induced Thrombocytopenia (HIT) : A Review of Contemporary Therapeutic Challenges in Clinical Practice. Malays J Med Sci (2008) 0.75
Reduced induction of anti-PF4/heparin antibody in RA patients after total knee arthroplasty. Arthritis Res Ther (2016) 0.75
Spontaneous heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages and pulmonary embolism after total knee arthroplasty. Arthroplast Today (2015) 0.75
Role of factor xa inhibitors in cancer-associated thrombosis: any new data? Adv Hematol (2011) 0.75
Atomic features of an autoantigen in heparin-induced thrombocytopenia (HIT). Autoimmun Rev (2016) 0.75
Successful management of acute thromboembolic disease complicated with heparin induced thrombocytopenia type II (HIT II): a case series. Thromb J (2008) 0.75
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 6.86
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med (2004) 4.52
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med (2002) 3.96
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.07
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med (2001) 2.54
Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet (1996) 2.20
Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 2.19
An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med (2003) 1.70
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood (2004) 1.63
Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost (1998) 1.53
A non-parametric test for interval-censored failure time data with application to AIDS studies. Stat Med (1996) 1.38
Heparin-induced thrombocytopenia. J Thromb Haemost (2003) 1.16
Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med (2001) 1.10
Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost (2005) 1.09
Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost (1995) 1.05
Generalizations of current status data with applications. Lifetime Data Anal (1995) 1.03
The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet (2002) 1.01
Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost (1992) 1.01
Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood (2002) 1.01
Mode of interaction between platelet factor 4 and heparin. Glycobiology (1993) 1.01
Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. Br J Haematol (2002) 0.95
Heparin-induced thrombocytopenia and thrombosis. N Engl J Med (1995) 0.92
Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. Thromb Res (2002) 0.91
The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol (1996) 0.90
Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med (1992) 0.89
Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica (2003) 0.88
Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood (1998) 0.85
The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost (1995) 0.84
Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia. Ann Oncol (2002) 0.83
Heparin-associated thrombocytopenia in a patient treated with polysulphated chondroitin sulphate: evidence for immunological crossreactivity between heparin and polysulphated glycosaminoglycan. Br J Haematol (1992) 0.81
Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol (2001) 0.81
Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost (1995) 0.80
Pentosan-induced thrombocytopenia: support for an immune complex mechanism. Br J Haematol (1994) 0.78
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet (2009) 4.28
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med (2002) 3.96
New gene functions in megakaryopoiesis and platelet formation. Nature (2011) 3.14
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst (2005) 3.08
Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.07
CLINICAL PRACTICE. Heparin-Induced Thrombocytopenia. N Engl J Med (2015) 3.06
Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med (2007) 2.97
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 2.56
CT and MRI early vessel signs reflect clot composition in acute stroke. Stroke (2011) 2.52
Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion (2003) 2.48
Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg (2003) 2.40
Continued sports activity, using a pain-monitoring model, during rehabilitation in patients with Achilles tendinopathy: a randomized controlled study. Am J Sports Med (2007) 2.31
Anucleate platelets generate progeny. Blood (2010) 2.24
Risk factors for hip fracture in older home care clients. J Gerontol A Biol Sci Med Sci (2009) 2.15
Acute achilles tendon rupture: a randomized, controlled study comparing surgical and nonsurgical treatments using validated outcome measures. Am J Sports Med (2010) 2.07
Donor exposures in recipients of pooled platelet concentrates. N Engl J Med (2013) 2.01
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol (2008) 1.98
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery. Thromb Haemost (2012) 1.94
A genome-wide association study identifies three loci associated with mean platelet volume. Am J Hum Genet (2008) 1.81
Middle cerebral artery occlusion in the rabbit using selective angiography: application for assessment of thrombolysis. Stroke (2008) 1.76
Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost (2009) 1.76
Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood (2010) 1.76
An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med (2003) 1.70
The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood (2009) 1.65
Multiple loci are associated with white blood cell phenotypes. PLoS Genet (2011) 1.65
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost (2008) 1.64
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol (2005) 1.58
Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. Blood (2013) 1.56
Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood (2006) 1.54
Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest (2002) 1.53
Reliability of electrocardiogram interpretation in critically ill patients. Crit Care Med (2006) 1.51
External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thromb Haemost (2014) 1.49
Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest (2005) 1.49
Fc(gamma) receptors IIa on cardiomyocytes and their potential functional relevance in dilated cardiomyopathy. J Am Coll Cardiol (2007) 1.48
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost (2010) 1.47
The Achilles tendon Total Rupture Score (ATRS): development and validation. Am J Sports Med (2006) 1.46
Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD. Blood (2012) 1.45
Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. Pharmacogenetics (2003) 1.45
Platelet transfusions in children: results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction. Transfusion (2002) 1.44
The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood (2013) 1.44
Heparin-induced thrombocytopenia: further evidence for a unique immune response. Blood (2012) 1.44
The Role for Optical Density in Heparin-Induced Thrombocytopenia: A Cohort Study. Chest (2015) 1.43
Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome. Transfus Med Rev (2003) 1.42
The diagnostic value of the anti-PF4/heparin immunoassay high-dose heparin confirmatory test in cardiac surgery patients. Anesth Analg (2011) 1.42
Dabigatran etexilate. Nat Rev Drug Discov (2008) 1.41
egc-Encoded superantigens from Staphylococcus aureus are neutralized by human sera much less efficiently than are classical staphylococcal enterotoxins or toxic shock syndrome toxin. Infect Immun (2004) 1.41
Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: will recent insight into pathogenesis translate into better treatment? Transfusion (2002) 1.40
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery. Clin Pharmacokinet (2008) 1.39
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost (2010) 1.39
Statistical methods for multivariate interval-censored recurrent events. Stat Med (2005) 1.38
A variant of the Sebastian platelet syndrome with unique neutrophil inclusions. Platelets (2002) 1.38
A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. Blood (2003) 1.38
Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med (2005) 1.38
Studies of the immune response in heparin-induced thrombocytopenia. Blood (2009) 1.37
Analysis of interval-censored disease progression data via multi-state models under a nonignorable inspection process. Stat Med (2010) 1.35
Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken) (2011) 1.35
MYH9-related platelet disorders. Semin Thromb Hemost (2009) 1.30
Profiling of alterations in platelet proteins during storage of platelet concentrates. Transfusion (2007) 1.30
The temporal profile of the anti-PF4/heparin immune response. Blood (2008) 1.28
The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica (2006) 1.27
Platelet transfusion in hematology, oncology and surgery. Dtsch Arztebl Int (2014) 1.26
A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood (2008) 1.25
Tests for multivariate recurrent events in the presence of a terminal event. Biostatistics (2004) 1.24
Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med (2003) 1.23
A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood (2012) 1.22
Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood (2002) 1.22
Staphylococcus aureus carriers neutralize superantigens by antibodies specific for their colonizing strain: a potential explanation for their improved prognosis in severe sepsis. J Infect Dis (2006) 1.21
Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev (2013) 1.20
Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med (2007) 1.20
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res (2006) 1.19
A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion (2007) 1.17
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist (2007) 1.16
Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy (2003) 1.16
Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. Blood (2013) 1.15
Regression analysis of multivariate panel count data. Biostatistics (2007) 1.15
Major functional deficits persist 2 years after acute Achilles tendon rupture. Knee Surg Sports Traumatol Arthrosc (2011) 1.15
The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood (2004) 1.15
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost (2010) 1.14
Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med (2003) 1.14
Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia. Transfusion (2010) 1.14
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol (2007) 1.11
Bivalirudin. Thromb Haemost (2008) 1.11